secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtaiBeckley Inc. (ATAI)
CIK:        0002081043
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001140361-26-000614
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26
--------------------------------------------------------------------------------

- BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.
- Additional BPL-003 Phase 2a cohort evaluating two-dose induction in TRD starts Q1'26; initial data expected Q4'26.
- VLS-01 (DMT buccal film) Phase 2 Elumina trial topline data from 142 TRD patients expected H2'26.
- EMP-01 (oral R-MDMA) SAD Phase 2a topline data expected Q1'26; new patent provides exclusivity through 2043.
- Redomiciliation to Delaware completed Dec 2025; added to NASDAQ biotech index (NBI) Dec 2025; cash runway into 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/0001140361-26-000614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/ef20062505_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer